Release date: 2017-10-25 If you want to say that the world's most widely used and most well-known drugs, aspirin is certainly one of them, and because of its wide range of uses, it is also the title of "century god medicine." This time, a research team from Taiwan found that people with hepatitis B, one of the most important risk factors for liver cancer, are less likely to develop liver cancer if they receive aspirin every day. Dr. Teng-Yu Lee, Principal Investigator of Gastroenterology, Taichung Veterans General Hospital, and his colleagues recently reported their findings at the American Association for the Study of Liver Diseases in Washington, DC. . Antiviral therapy does not completely eliminate hepatitis B risk Hepatitis B is a liver infection caused by hepatitis B virus (HBV). It is estimated that approximately 257 million people worldwide are infected with hepatitis B virus. According to the Centers for Disease Control and Prevention (CDC), approximately 15 - 25% of patients with chronic hepatitis B develop severe liver disease such as cirrhosis or liver cancer. In the United States, for example, about 1,800 people die each year from liver diseases associated with hepatitis B. Although some antiviral therapies can help reduce the risk of liver cancer in patients with hepatitis B, Dr. Lee and the research team point out that these drugs do not completely eliminate the risk of hepatitis B. More importantly, they noticed that some people infected with HBV are not suitable for taking antiviral drugs, so it is necessary to use alternative therapies to reduce the risk of liver cancer in these patients. Prior to this, studies have shown that aspirin can reduce the risk of cancer, but few studies have investigated the impact of this drug on liver cancer. Therefore, Dr. Lee and the team conducted a large cohort study to assess the association of aspirin therapy with HBV-related liver cancer. The risk of liver cancer is reduced by one third The researchers used the 1998-2012 Taiwan National Health Insurance Research Database to analyze the medical records of 204,507 patients with chronic hepatitis B. Then, 1553 patients with at least 90 days of daily aspirin therapy and no liver cancer before treatment were identified. These patients matched a ratio of 1:4 to 6212 patients who had not received any form of antiplatelet therapy. The researchers then observed the cumulative incidence of hepatocellular carcinoma (HCC) in these patients over a five-year period and their overall risk of developing liver cancer. The study found that patients who received daily aspirin had a much lower incidence of liver cancer than those who did not receive treatment, at 5.59% and 2.86%, respectively. Patients who received daily aspirin treatment also had a 37% lower risk of developing HCC compared with untreated patients. However, further research is needed to confirm the benefits of aspirin in the treatment of hepatitis B patients, but Dr. Lee and the research team believe that their findings have brought hope. "In order to effectively prevent HBV-related liver cancer, the findings of this study may help hepatologists treat patients with chronic hepatitis B virus infection in the future, especially for those who do not use antiviral therapy." Source: Bio-Exploration Ptz Camera,Cloud Storage Ptz Camera,Security Low Power Camera,Ip Camera Wifi Wireless Shenzhen Zuomi Technology Co., Ltd. , https://www.zuomicamera.com